Monograph

L01XA02 - Carboplatin

Not porphyrinogenic

Rationale

Non-CYP metabolism. However, side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Chemical description

Carboplatin is a platinum coordination compound composed of a platinum atom surrounded in a plane by 2 ammonia groups and 2 other ligands in the cis position(diaminocyclobutane dicarboxy platinium).

Therapeutic characteristics

Carboplatin is a platinum-containing antineoplastic agent used in the treatment of ovarian tumours, lung cancer and certain head and neck cancers. It is administered as an intravenous infusion. Common adverse reactions of carboplatin that can be confused with an acute porphyric attack are vomiting, nausea, GI pain, and constipation. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Metabolism and pharmacokinetics

Carboplatin is mainly excreted unchanged by the kidneys. Partly non-enzymatically degraded. No reports of drug interactions pointing to CYP-metabolism. Not listed by Rendic (2002) as CYP-inducer or inhibitor. Carboplatin did not exert a significant effect on the PXR-mediated induction of CYP3A4 (Harmsen, 2009). Carboplatin was without inhibitory effect on CYP3A4 (Baumhakel, 2001).

Published experience

Used uneventfully in AIP woman in the treatment of squamous cell carcinoma of the uterus (Thiery-Vuillemin, 2008).

IPNet drug reports

Uneventful use reported in 1 patient with acute porphyria.

References

#	Citation details	PMID
*	Scientific articles
1.	Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448.
2.	Thiery-Vuillemin, A, Chaigneau, L, et al. Anticancer therapy in patients with porphyrias: evidence today. Expert Opin Drug Saf 2008; 7(2):159-165.
3.	Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes. Baumhäkel M, Kasel D, et al. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28.
4.	Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Harmsen S, Meijerman I, et al. Cancer Chemother Pharmacol. 2009;64(1):35-43.	18839173
*	Drug reference publications
5.	McEvoy GK, editor.Carboplatin. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (10.05.10).
6.	Sweetman SC, editor. Martindale: The complete drug reference. Carboplatin. Pharmaceutical Press 2009.

Citation details

PMID

Scientific articles

Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448.

Thiery-Vuillemin, A, Chaigneau, L, et al. Anticancer therapy in patients with porphyrias: evidence today. Expert Opin Drug Saf 2008; 7(2):159-165.

Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes.

Baumhäkel M, Kasel D, et al. Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28.

Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor.

Harmsen S, Meijerman I, et al. Cancer Chemother Pharmacol. 2009;64(1):35-43.

18839173

Drug reference publications

McEvoy GK, editor.Carboplatin. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (10.05.10).

Sweetman SC, editor. Martindale: The complete drug reference. Carboplatin. Pharmaceutical Press 2009.

Similar drugs

Explore alternative drugs in similar therapeutic classes L01X / L01XA or go back.

Tradenames and packages

From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Netherlands

Carboplatin · Carboplatin Accord 10 mg/ml, concentraat voor oplossing voor infusie · Carboplatine · Carboplatine Fresenius Kabi 10 mg/ml, concentraat voor oplossing voor infusie · Carboplatine Hikma 10 mg/ml oplossing voor infusie

Belgium

Carboplatin · Carboplatin Accord Healthcare 10 mg/ml sol. perf. (à diluer) i.v. flac. · Carboplatin Eugia 10 mg/ml sol. perf. (à diluer) i.v. flac. · Carboplatine · Carboplatine Fresenius Kabi 10 mg/ml sol. perf. (à diluer) i.v. flac. · Carboplatine Hikma 150 mg/15 ml sol. perf. i.v. flac. · Carboplatine Hikma 450 mg/45 ml sol. perf. i.v. flac. · Carboplatine Hikma 50 mg/5 ml sol. perf. i.v. flac. · Carboplatine Hikma 600 mg/60 ml sol. perf. i.v. flac. · Carboplatine Onco-Tain · Carboplatine Hospira Onco-Tain 150 mg/15 ml sol. inj./perf. i.v. flac. · Carboplatine Hospira Onco-Tain 450 mg/45 ml sol. inj./perf. i.v. flac. · Carboplatine Hospira Onco-Tain 600 mg/60 ml sol. inj./perf. i.v. flac. · Carboplatinum · Carboplatinum Hikma Farmacêutica 150 mg sol. perf. (à diluer) i.v. flac. · Carboplatinum Hikma Farmacêutica 450 mg sol. perf. (à diluer) i.v. flac. · Carboplatinum Hikma Farmacêutica 50 mg sol. perf. (à diluer) i.v. flac. · Carbosin · Carbosin 150 mg sol. perf. (à diluer) i.v. flac. · Carbosin 450 mg sol. perf. (à diluer) i.v. flac. · Carbosin 50 mg sol. perf. (à diluer) i.v. flac. · Carbosin 600 mg sol. perf. (à diluer) i.v. flac.

United Kingdom

Carboplatin · Carboplatin 100mg/250ml in Glucose 5% infusion bags · Carboplatin 110mg/250ml in Glucose 5% infusion bags · Carboplatin 1130mg/500ml in Glucose 5% infusion bags · Carboplatin 120mg/500ml in Glucose 5% infusion bags · Carboplatin 1280mg/500ml in Glucose 5% infusion bags · Carboplatin 130mg/500ml in Glucose 5% infusion bags · Carboplatin 1450mg/500ml in Glucose 5% infusion bags · Carboplatin 150mg/15ml concentrate for solution for infusion vials · Carboplatin 150mg/15ml solution for infusion vials · Carboplatin 150mg/500ml in Glucose 5% infusion bags · Carboplatin 160mg/500ml in Glucose 5% infusion bags · Carboplatin 1640mg/500ml in Glucose 5% infusion bags · Carboplatin 180mg/500ml in Glucose 5% infusion bags · Carboplatin 1850mg/1000ml in Glucose 5% infusion bags · Carboplatin 200mg/500ml in Glucose 5% infusion bags · Carboplatin 2090mg/1000ml in Glucose 5% infusion bags · Carboplatin 220mg/500ml in Glucose 5% infusion bags · Carboplatin 240mg/500ml in Glucose 5% infusion bags · Carboplatin 270mg/500ml in Glucose 5% infusion bags · Carboplatin 300mg/500ml in Glucose 5% infusion bags · Carboplatin 330mg/500ml in Glucose 5% infusion bags · Carboplatin 400mg/500ml in Glucose 5% infusion bags · Carboplatin 450mg/45ml concentrate for solution for infusion vials · Carboplatin 450mg/45ml solution for infusion vials · Carboplatin 500mg/500ml in Glucose 5% infusion bags · Carboplatin 50mg/5ml concentrate for solution for infusion vials · Carboplatin 50mg/5ml solution for infusion vials · Carboplatin 560mg/500ml in Glucose 5% infusion bags · Carboplatin 600mg/60ml concentrate for solution for infusion vials · Carboplatin 600mg/60ml solution for infusion vials · Carboplatin 630mg/500ml in Glucose 5% infusion bags · Carboplatin 66mg/250ml in Glucose 5% infusion bags · Carboplatin 700mg/500ml in Glucose 5% infusion bags · Carboplatin 74mg/250ml in Glucose 5% infusion bags · Carboplatin 890mg/500ml in Glucose 5% infusion bags · Carboplatin 90mg/250ml in Glucose 5% infusion bags · Carboplatin 1000mg/500ml in Glucose 5% infusion bags · Carboplatin 140mg/500ml in Glucose 5% infusion bags · Carboplatin 360mg/500ml in Glucose 5% infusion bags · Carboplatin 450mg/500ml in Glucose 5% infusion bags · Carboplatin 790mg/500ml in Glucose 5% infusion bags · Carboplatin 82mg/250ml in Glucose 5% infusion bags · Paraplatin · Paraplatin 150mg/15ml solution for infusion vials · Paraplatin 450mg/45ml solution for infusion vials · Paraplatin 50mg/5ml solution for infusion vials · Paraplatin 600mg/60ml solution for infusion vials

Denmark